S.No | drugs delivery (IND) | Product Development | Preclinical Testing | Commercial License (IP) |
1 | LBPL-1 Lysilirag-1 drug for treating type 2 diabetes in obese |
100% Complete
| 2025 | |
2 | LBPL-2 Lystictide-NPPA Congestive Heart Failure (IND) |
100% Complete
| 2025 | |
3 | LBPL-3 Lysspon-1- Alzheimer's (IND) |
100% Complete
| 2025 |
S.No | LBPL Biosimilar Pipeline | Product Development | Preclinical Testing | Commercial License (IP) |
1 | LBPL-1 Pembrolizumab |
100% Complete
| 2024 | |
2 | LBPL-2 Caplacizumab |
100% Complete
| 2024 | |
3 | LBPL-3 Teriparatide |
100% Complete
| 2024 | |
4 | LBPL-4 Adalimumab |
100% Complete
| 2024 | |
5 | LBPL-5 Ranibizumab |
100% Complete
| 2024 | |
6 | LBPL-6 Pegfilgrastim |
100% Complete
| 2024 | |
7 | LBPL-7 insulin glargine |
100% Complete
| 2024 |
S.No | Lysvimab for RBD SPIKE COVID and RNA-Targeted small panantipeptide viral drugs for PAN-COVID | Product Development | Preclinical Testing | Commercial License (IP) |
1 | LBPLVIR-1 Development of Alpha, Beta, Gamma, Delta, lamda & Omicron specific Lysvimab-RBD SPIKE for treatment of COVID-19. |
100% Complete
| 2024 | |
2 | LBPL-1 Development of Beta, Gamma, Delta, lamda & Omicron 1st Thirty-in-One GeneX viral-based RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. |
100% Complete
| 2027 | |
3 | LBPL-2 Development of Alpha, Delta & lamda 2nd Fifteen-in-One GeneX viral-based RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. |
100% Complete
| 2027 | |
4 | LBPL-3 Development of Alpha, Delta & lamda 3rd Twenty-Five-in-One GeneX viral-based RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. |
100% Complete
| 2027 |
S.No | LBPLPANCOVAC-1 Development of Beta, Gamma, Delta, lamda & Omicron 1st Thirty-in-One GeneX viral-based Recombinant Unique antigen peptide PANCOVAC and LBPLPANCOVIR-2 RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID | Product Development | Preclinical Testing | Commercial License (IP) |
1 | SARS-CoV-2 |
100% Complete
| 2027 | |
2 | SARS-CoV-1 |
100% Complete
| 2027 | |
3 | Human coronavirus OC43 |
100% Complete
| 2027 | |
4 | Human coronavirus HKU1 |
100% Complete
| 2027 | |
5 | Middle East respiratory syndrome-related coronavirus |
100% Complete
| 2027 | |
6 | Infectious bronchitis coronavirus (Avian coronavirus) |
100% Complete
| 2027 | |
7 | Turkey coronavirus (Avian coronavirus) |
100% Complete
| 2027 | |
8 | Duck coronavirus (Avian coronavirus) |
100% Complete
| 2027 | |
9 | Betacoronavirus HKU24 |
100% Complete
| 2027 | |
10 | Bovine coronavirus isolate BCoV-ENT |
100% Complete
| 2027 | |
11 | Betacoronavirus 1 |
100% Complete
| 2027 | |
12 | Murine hepatitis virus strain MHV-A59 C12 mutant |
100% Complete
| 2027 | |
13 | Canada goose coronavirus strain Cambridge_Bay_2017 |
100% Complete
| 2027 | |
14 | Bulbul coronavirus HKU11 |
100% Complete
| 2027 | |
15 | Rabbit coronavirus HKU14 |
100% Complete
| 2027 | |
16 | Bat coronavirus BM48-31/BGR/2008 |
100% Complete
| 2027 | |
17 | Tylonycteris bat coronavirus HKU4 |
100% Complete
| 2027 | |
18 | Rousettus bat coronavirus isolate GCCDC1 356 |
100% Complete
| 2027 | |
19 | Rousettus bat coronavirus HKU9 |
100% Complete
| 2027 | |
20 | BtPa-BetaCoV/GD2013 |
100% Complete
| 2027 | |
21 | BtRf-BetaCoV/HeB2013 |
100% Complete
| 2027 | |
22 | BtRf-BetaCoV/JL2012 |
100% Complete
| 2027 | |
23 | BtRf-BetaCoV/SX2013 |
100% Complete
| 2027 | |
24 | BtRs-BetaCoV/GX2013 |
100% Complete
| 2027 | |
25 | BtRs-BetaCoV/HuB2013 |
100% Complete
| 2027 | |
26 | BtRs-BetaCoV/YN2013 |
100% Complete
| 2027 | |
27 | BtTp-BetaCoV/GX2012 |
100% Complete
| 2027 | |
28 | Bat Hp-betacoronavirus/Zhejiang2013 |
100% Complete
| 2027 | |
29 | Betacoronavirus Erinaceus/VMC/DEU/2012 |
100% Complete
| 2027 | |
30 | Pipistrellus bat coronavirus HKU5 |
100% Complete
| 2027 |
S.No | LBPLPANCOVAC-2 Development of Alpha, Delta & lamda 2nd Fifteen-in-One GeneX viral-based Recombinant Unique PANCOVAC and LBPLPANCOVIR-3 RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. | Product Development | Preclinical Testing | Commercial License (IP) |
1 | Human coronavirus 229E |
100% Complete
| 2027 | |
2 | Bat coronavirus |
100% Complete
| 2027 | |
3 | Camel alphacoronavirus isolate camel/Riyadh/Ry141/2015 |
100% Complete
| 2027 | |
4 | 229E-related bat coronavirus |
100% Complete
| 2027 | |
5 | Unidentified human coronavirus |
100% Complete
| 2027 | |
6 | Swine acute diarrhea syndrome related coronavirus |
100% Complete
| 2027 | |
7 | Swine enteric alphacoronavirus |
100% Complete
| 2027 | |
8 | Porcine enteric alphacoronavirus |
100% Complete
| 2027 | |
9 | Rhinolophus bat coronavirus HKU2 |
100% Complete
| 2027 | |
10 | Rhinolophus affinis bat coronavirus HKU2 |
100% Complete
| 2027 | |
11 | Alpaca respiratory coronavirus |
100% Complete
| 2027 | |
12 | BtRf-AlphaCoV/YN2012 |
100% Complete
| 2027 | |
13 | Bottlenose dolphin coronavirus |
100% Complete
| 2027 | |
14 | Bat alphacoronavirus |
100% Complete
| 2027 | |
15 | Beluga Whale coronavirus SW1 |
100% Complete
| 2027 |
S.No | LBPLPANCOVAC-3 Development of Alpha, Delta & lamda 3rd Twenty-Five-in-One GeneX viral-based Recombinant Unique PANCOVAC and LBPLPANCOVIR-4 RNA-Targeted small Unique panantipeptide viral Drug to treat severe cases of PAN-COVID. | Product Development | Preclinical Testing | Commercial License (IP) |
1 | Human coronavirus NL63 |
100% Complete
| 2027 | |
2 | Ferret coronovirus |
100% Complete
| 2027 | |
3 | Mink coronavirus strain WD1127 |
100% Complete
| 2027 | |
4 | Bat coronavirus |
100% Complete
| 2027 | |
5 | Miniopterus schreibersii bat coronavirus 1 |
100% Complete
| 2027 | |
6 | Feline infectious peritonitis |
100% Complete
| 2027 | |
7 | BtMr-AlphaCoV/SAX2011 |
100% Complete
| 2027 | |
8 | BtRf-AlphaCoV/HuB2013 |
100% Complete
| 2027 | |
9 | BtNv-AlphaCoV/SC2013 |
100% Complete
| 2027 | |
10 | Bat coronavirus CDPHE15/USA/2006 |
100% Complete
| 2027 | |
11 | Myotis lucifugus coronavirus |
100% Complete
| 2027 | |
12 | Scotophilus kuhlii bat coronavirus 512 |
100% Complete
| 2027 | |
13 | Transmissible gastroenteritis. |
100% Complete
| 2027 | |
14 | Porcine epidemic diarrhea virus |
100% Complete
| 2027 | |
15 | Lucheng Rn rat coronavirus isolate Lucheng-19 |
100% Complete
| 2027 | |
16 | Bat coronavirus 1A |
100% Complete
| 2027 | |
17 | Bat coronavirus 1B |
100% Complete
| 2027 | |
18 | Bat coronavirus CDPHE15/USA/2006 |
100% Complete
| 2027 | |
19 | Coronavirus AcCoV-JC34 |
100% Complete
| 2027 | |
20 | Hipposideros pomona bat coronavirus CHB25 |
100% Complete
| 2027 | |
21 | NL63-related bat coronavirus |
100% Complete
| 2027 | |
22 | BtNv-AlphaCoV/SC2013 |
100% Complete
| 2027 | |
23 | Rousettus bat coronavirus HKU10 |
100% Complete
| 2027 | |
24 | Alphacoronavirus Bat-CoV/P.kuhlii/Italy/3398-19/2015 |
100% Complete
| 2027 | |
25 | Wencheng Sm shrew coronavirus |
100% Complete
| 2027 |
S.No | Protein subunit vaccine | Product Development | Preclinical Testing | Commercial License (IP) |
1 | LBPLVAC-4 Protein subunit vaccine four in one Dengue 1-4 |
100% Complete
| 2025 | |
2 | LBPLVAC-5 Protein subunit vaccine Chikungunya |
100% Complete
| 2025 | |
3 | LBPLVAC-6 Protein subunit vaccine Sporozoite & Circumsporozoite (malaria) |
100% Complete
| 2025 | |
4 | LBPLVAC-7 Protein subunit vaccine insulin (IlGF) (SGIV) |
90% Complete
| 2025 |